KAS
SYRE icon

Kemnay Advisory Services’s Spyre Therapeutics SYRE Stock Holding History

Kemnay Advisory Services’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.8K Buy
741
+167
+29% +$12.2K 0.01% 232
2026
Q1 		$29K Buy
+574
New +$21.6K ﹤0.01% 464

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Kemnay Advisory Services's SYRE Position: Q2 2026 in Review

Kemnay Advisory Services increased its Spyre Therapeutics (SYRE) stake by 29% in Q2 2026, buying an estimated $12.2K and bringing the position to 741 shares worth $65.8K. The position accounts for 0.01% of the portfolio, ranked #232.

Kemnay Advisory Services first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Kemnay Advisory Services held 741 shares of Spyre Therapeutics worth $65.8K as of Q2 2026.
  • Kemnay Advisory Services bought 167 Spyre Therapeutics shares in Q2 2026, an estimated $12.2K.
  • Spyre Therapeutics made up 0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #232 holding.
  • Kemnay Advisory Services first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.